GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth
This article was originally published in The Tan Sheet
Executive Summary
The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth
You may also be interested in...
OTC, Rx Drug Risk Equation May Be Altered In Upcoming GMP Plan
FDA is considering applying different levels of scrutiny to OTC and Rx drugs as part of its new risk-based approach to pharmaceutical Good Manufacturing Practices
OTC, Rx Drug Risk Equation May Be Altered In Upcoming GMP Plan
FDA is considering applying different levels of scrutiny to OTC and Rx drugs as part of its new risk-based approach to pharmaceutical Good Manufacturing Practices
OTC, Rx Drug Risk Equation May Be Altered In Upcoming GMP Plan
FDA is considering applying different levels of scrutiny to OTC and Rx drugs as part of its new risk-based approach to pharmaceutical Good Manufacturing Practices